Press - MIG Verwaltung EN

Handelsblatt - Thu, 02. July 2020

Biotech-Firm Immatics from Tübingen with Nasdaq Listing

„Handelsblatt.com“ reports about the Listing of MIG-portfolio company Immatics at New Yorks Nasdaq.

Find out more

FOCUS - Thu, 02. July 2020

Biontech Vaccine: Good data creat hope in turnaround

„Focus“ and other media report about good results of BioNTech, a MIG portfolio company, in search of a vaccine against Covid-19.

Find out more

Manager Magazin - Mon, 29. June 2020

Singapurs Funds Temasek invests in BioNTech

„Manager Magazin“ reports about a 250 million investment of Temasek in BioNTech, a MIG portfolio company.

Find out more

FAZ - Mon, 15. June 2020

„It´s not a question to participate in a race“

„Süddeutschen Zeitung“ interviews Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, about the state of the art in developing a vaccine against Covid-19.

Find out more

FOCUS, Heft 23/2020 - Sat, 30. May 2020

The next quantum leap

In an article in detail „Focus“ describes the state of the art of quantum computing in Europe and mentions MIG portfolio company IQM as a main player.

Focus - Fri, 15. May 2020

Costs nothing, not destroyable

Magazine „Focus“ reports, how Airbus will beat Boing with new materials from Amsilk, a MIG-portfolio company.

Find out more

EU-Startups - Thu, 14. May 2020

10 promising European deeptech startups leading us into the future

Platform „EU-Startups“ provides an overview of European „deeptech startups“ and highlights MIG-portfolio company IQM and the founder Dr. Jan Goetz.

Find out more

Manager Magazin - Thu, 14. May 2020

Biontech expects first data til July in their development of a vaccine against Covid-19

Several media reports new steps of BioNTech, a MIG portfolio company, in search of a vaccine against the new Coronavirus.

Find out more

Gründerszene - Wed, 13. May 2020

The start-up of this German build hardware for Quantumcomputers

„Gründerszene“ portrays Dr. Jan Goetz, CEO of IQM, a MIG portfolio company.

Find out more

Tagesschau, FAZ and other media - Wed, 22. April 2020

First clinical study for a Corona-Vaccine in Germany approved

FAZ and other media report, that in Germany for the first time a clinical study got the approval to test a Corona-Vaccine. MIG-Portfolio company BioNTech is allowed to start tests of his vaccine with volunteers.

Find out more

Handelsblatt - Thu, 09. April 2020

Biontech and Pfizer are planning to produce millions of units of Corona-vaccine this year

Handelsblatt.com reports about the plans of BioNTech, a portfolio company of MIG Fonds, to develop and produce a vaccine against Covid-19 together with Pfizer.

Find out more

Manager Magazin - Tue, 31. March 2020

Power-Paar against SARS-CoV-2

„Manager Magazin Online“ portrays Ugur Sahin and Özlem Türeci of BioNTech and acknowledge the role of MIG Fonds in founding and financing the firm.

Find out more

DIE ZEIT - Wed, 25. March 2020

Saving the World

Weekly Magazine „DIE ZEIT“ reports about pharmaceutical companies searching for vaccines against SARS CoV-2 focusing on BioNTech, a MIG portfolio company.

Find out more

Going Public Media - Sat, 21. March 2020

AFFiRiS erhält Patent für Parkinson-Medikament in China

„Going Public“ reports about progresses of MIG portfolio company AFFiRiS. The biotech firm, based in Vienna, got a patent in China and will start a clinical study (Parkinson) in the second half of the year.

Find out more

Financial Times - Fri, 20. March 2020

Ugur Sahin : the immunologist racing to find a vaccine

„Financial Times“ portrays Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, who started the race to find the first vaccine against SARS CoV-2.

Find out more

transkript, Finanzwelt und andere - Wed, 18. March 2020

Immatics is planning a listing on the Nasdaq

Several national and international media are reporting about the IPO-plans of MIG portfolio company Immatics in Q2. on the Nasdaq.

Find out more

Reuters, Handelsblatt, FAZ - Mon, 16. March 2020

BioNTech in China alliance with Fosun over coronavirus vaccine candidate

Newswire „Reuters“ reports about a cooperation of BioNTech, a MIG portfolio company. Together with Fosun Pharmaceutical a vaccine against Covid-19 should be developed first in China.

Find out more

Life Science - Sun, 15. March 2020

The IPO took BioNTech onto the international stage

„Life Sciences“ is interviewing Sierk Pötting, BioNTech SE, and Michael Motschmann, General Partner der MIG AG, about the success of BioNTech.

Mehr erfahren

Reuters - Fri, 06. March 2020

Pfizer weighs working with BioNTech on potential coronavirus vaccine

Reuters reports, that Pfizer weighs working with MIG portfolio company BioNTech on a potential coronavirus vaccine.

Find out more

Finanzwelt - Wed, 04. March 2020

Third Investment of MIG 16

Trade magazine „Finanzwelt“ reports about MIG Fonds newest investment in Neracare GmbH.

Find out more

OLED Brief - Tue, 03. March 2020

Cynora introduces fluorescent blue emitter

Trade magazine „OLED-Brief“ reports about the first commercial OLED-product of Cynora, a MIG portfolio company.

Find out more

transkript - Thu, 20. February 2020

Immatics closes second TCR-T-Billion Deal

Trade Magazine „transkript“ reports about a deal between immatics, a MIG porfolio company, and GlaxoSmithKline, which assures immatics milestone payments up to 1.1 Billion US Dollar.

Find out more

Finanzwelt - Tue, 11. February 2020

„We align our portfolio along trends of the future“

„Finanzwelt“ reports about the year 2019 of MIG AG.

Find out more

Gründerszene - Wed, 29. January 2020

„For me it would not be enough to sell shoes online“

Interview with Gloria Seibert, founder of Temedica, a new MIG portfolio company.

Find out more

transkript - Mon, 20. January 2020

Advancecor achieves good data of Revacept

Trade magazine „transkript“ reports about a successful phase-II-study of biontech-firm AdvanceCOR, a MIG portfolio company.

Find out more

Wirtschaftswoche, Munich Start-up, Going Public Media, kma, Gründerszene - Tue, 14. January 2020

MIG - Press Review

2020

Biotech-Firm Immatics from Tübingen with Nasdaq Listing

„Handelsblatt.com“ reports about the Listing of MIG-portfolio company Immatics at New Yorks Nasdaq.

Biontech Vaccine: Good data creat hope in turnaround

„Focus“ and other media report about good results of BioNTech, a MIG portfolio company, in search of a vaccine against Covid-19.

„Manager Magazin“ reports about a 250 million investment of Temasek in BioNTech, a MIG portfolio company.

„It´s not a question to participate in a race“

„Süddeutschen Zeitung“ interviews Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, about the state of the art in developing a vaccine against Covid-19.

The next quantum leap

In an article in detail „Focus“ describes the state of the art of quantum computing in Europe and mentions MIG portfolio company IQM as a main player.

Costs nothing, not destroyable

Magazine „Focus“ reports, how Airbus will beat Boing with new materials from Amsilk, a MIG-portfolio company.

10 promising European deeptech startups leading us into the future

Platform „EU-Startups“ provides an overview of European „deeptech startups“ and highlights MIG-portfolio company IQM and the founder Dr. Jan Goetz.

Several media reports new steps of BioNTech, a MIG portfolio company, in search of a vaccine against the new Coronavirus.

The start-up of this German build hardware for Quantumcomputers

„Gründerszene“ portrays Dr. Jan Goetz, CEO of IQM, a MIG portfolio company.

First clinical study for a Corona-Vaccine in Germany approved

FAZ and other media report, that in Germany for the first time a clinical study got the approval to test a Corona-Vaccine. MIG-Portfolio company BioNTech is allowed to start tests of his vaccine with volunteers.

Biontech and Pfizer are planning to produce millions of units of Corona-vaccine this year

Handelsblatt.com reports about the plans of BioNTech, a portfolio company of MIG Fonds, to develop and produce a vaccine against Covid-19 together with Pfizer.

„Manager Magazin Online“ portrays Ugur Sahin and Özlem Türeci of BioNTech and acknowledge the role of MIG Fonds in founding and financing the firm.

Saving the World

Weekly Magazine „DIE ZEIT“ reports about pharmaceutical companies searching for vaccines against SARS CoV-2 focusing on BioNTech, a MIG portfolio company.

AFFiRiS erhält Patent für Parkinson-Medikament in China

„Going Public“ reports about progresses of MIG portfolio company AFFiRiS. The biotech firm, based in Vienna, got a patent in China and will start a clinical study (Parkinson) in the second half of the year.

Ugur Sahin : the immunologist racing to find a vaccine

„Financial Times“ portrays Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, who started the race to find the first vaccine against SARS CoV-2.

Immatics is planning a listing on the Nasdaq

Several national and international media are reporting about the IPO-plans of MIG portfolio company Immatics in Q2. on the Nasdaq.

BioNTech in China alliance with Fosun over coronavirus vaccine candidate

Newswire „Reuters“ reports about a cooperation of BioNTech, a MIG portfolio company. Together with Fosun Pharmaceutical a vaccine against Covid-19 should be developed first in China.

The IPO took BioNTech onto the international stage

„Life Sciences“ is interviewing Sierk Pötting, BioNTech SE, and Michael Motschmann, General Partner der MIG AG, about the success of BioNTech.

Pfizer weighs working with BioNTech on potential coronavirus vaccine

Reuters reports, that Pfizer weighs working with MIG portfolio company BioNTech on a potential coronavirus vaccine.

Third Investment of MIG 16

Trade magazine „Finanzwelt“ reports about MIG Fonds newest investment in Neracare GmbH.

Cynora introduces fluorescent blue emitter

Trade magazine „OLED-Brief“ reports about the first commercial OLED-product of Cynora, a MIG portfolio company.

Immatics closes second TCR-T-Billion Deal

Trade Magazine „transkript“ reports about a deal between immatics, a MIG porfolio company, and GlaxoSmithKline, which assures immatics milestone payments up to 1.1 Billion US Dollar.

„We align our portfolio along trends of the future“

„Finanzwelt“ reports about the year 2019 of MIG AG.

„For me it would not be enough to sell shoes online“

Interview with Gloria Seibert, founder of Temedica, a new MIG portfolio company.

Advancecor achieves good data of Revacept

Trade magazine „transkript“ reports about a successful phase-II-study of biontech-firm AdvanceCOR, a MIG portfolio company.

Series B Funding of Temedica

Several media report about the 17 million Euro series-B-financing round of Temedica, which was led by MIG Fonds.